Scleroderma (Limited and Diffuse)
8
4
4
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
12.5%
1 terminated out of 8 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Evaluating the Effect of Questionnaire Context on the Reporting of Somatic Items Among People With Systemic Sclerosis
Metabolomic Analysis of Systemic Sclerosis
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
Respiratory Muscle Training in Scleroderma